Back to Results

Drugs Made In America Acquisition (DMAA)

Featured in Small-Cap Stocks

Drugs Made In America Acquisition Corp. is a NASDAQ-listed common stock issuer with no significant operating business. The company was formed in 2024 and is based in Fort Lauderdale, Florida. As a special purpose acquisition company, it aims to complete a business combination through a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or a similar transaction with one or more businesses.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-DMAA
$9.65
-9.8% Downside
Fair
—
—
—
Fair
—
—
—
0.0%
August 13, 2026
54.2x
-48.9x
—
360.8 M
360.9 M
0.0%
82.7%
0.8
—
-5.7%
Send a message
Valuation • Fair Value

Drugs Made In America Acquisition (NASDAQ-DMAA) Fair Value by Valuation Model

Compare the primary fair value estimate for Drugs Made In America Acquisition (NASDAQ-DMAA) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$9.65

Estimated downside of 9.8% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$2.19

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$9.65

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Drugs Made In America Acquisition (NASDAQ-DMAA) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Drugs Made In America Acquisition (NASDAQ-DMAA)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Drugs Made In America Acquisition (NASDAQ-DMAA) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Drugs Made In America Acquisition (NASDAQ-DMAA)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

0.8

Lower score that deserves closer risk review.

FCF / Net Income

-5.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Drugs Made In America Acquisition (NASDAQ-DMAA). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Drugs Made In America Acquisition (NASDAQ-DMAA)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 13, 2026

Days to Earnings

23

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Drugs Made In America Acquisition (NASDAQ-DMAA), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Drugs Made In America Acquisition (NASDAQ-DMAA) Stock Forecast & Technical Outlook

Review Drugs Made In America Acquisition (NASDAQ-DMAA) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Drugs Made In America Acquisition (NASDAQ-DMAA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Drugs Made In America Acquisition (NASDAQ-DMAA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Drugs Made In America Acquisition (NASDAQ-DMAA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Drugs Made In America Acquisition (NASDAQ-DMAA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Drugs Made In America Acquisition (NASDAQ-DMAA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Drugs Made In America Acquisition (NASDAQ-DMAA)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Drugs Made In America Acquisition (NASDAQ-DMAA) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

Drugs Made In America Acquisition (NASDAQ-DMAA) Stock FAQ

Quick answers about Drugs Made In America Acquisition (NASDAQ-DMAA) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$9.65
Estimated downside 9.8%
Valuation Rating
Overvalued
Estimated downside of 9.8%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Fair
Current financial-health read

The current fair value estimate for Drugs Made In America Acquisition (NASDAQ-DMAA) is $9.65. This implies an estimated downside of 9.8% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 9.8% versus the current market price.

An analyst price target for Drugs Made In America Acquisition (NASDAQ-DMAA) is not currently available in the latest data file.

The current financial health read for Drugs Made In America Acquisition (NASDAQ-DMAA) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Drugs Made In America Acquisition (NASDAQ-DMAA) is August 13, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Drugs Made In America Acquisition (NASDAQ-DMAA) is 54.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Drugs Made In America Acquisition is 360.8 M.

The current enterprise value listed for Drugs Made In America Acquisition is 360.9 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Drugs Made In America Acquisition is NASDAQ-DMAA, and the stock is listed on NASDAQ.

Drugs Made In America Acquisition (NASDAQ-DMAA) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Drugs Made In America Acquisition is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Drugs Made In America Acquisition is 82.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Capital Markets Stocks on NASDAQ View more

Interactive Brokers Group Inc (IBKR) Interactive Brokers Group Inc (IBKR)
Robinhood Markets Inc (HOOD) Robinhood Markets Inc (HOOD)
CME Group Inc (CME) CME Group Inc (CME)
Nasdaq Inc (NDAQ) Nasdaq Inc (NDAQ)
Coinbase Global Inc (COIN) Coinbase Global Inc (COIN)
Northern Trust Corp ADR (NTRSO) Northern Trust Corp ADR (NTRSO)
Northern Trust Corporation (NTRS) Northern Trust Corporation (NTRS)
LPL Financial Holdings Inc (LPLA) LPL Financial Holdings Inc (LPLA)
T. Rowe Price Group Inc (TROW) T. Rowe Price Group Inc (TROW)
Tradeweb Markets Inc (TW) Tradeweb Markets Inc (TW)
Brookfield Property Partners LP (BPYPO) Brookfield Property Partners LP (BPYPO)
Brookfield Property Partners LP (BPYPP) Brookfield Property Partners LP (BPYPP)
Brookfield Property Partners LP PR (BPYPN) Brookfield Property Partners LP PR (BPYPN)
TPG Inc (TPG) TPG Inc (TPG)
Carlyle Group Inc (CG) Carlyle Group Inc (CG)
Futu Holdings Ltd (FUTU) Futu Holdings Ltd (FUTU)
Ares Capital Corporation (ARCC) Ares Capital Corporation (ARCC)
SEI Investments Company (SEIC) SEI Investments Company (SEIC)
Freedom Holding Corp (FRHC) Freedom Holding Corp (FRHC)
Galaxy Digital Inc (GLXY) Galaxy Digital Inc (GLXY)
Xp Inc (XP) Xp Inc (XP)
Stonex Group Inc (SNEX) Stonex Group Inc (SNEX)
Morningstar Inc (MORN) Morningstar Inc (MORN)
Victory Capital Holdings Inc (VCTR) Victory Capital Holdings Inc (VCTR)